AUTHORS
Josh Schwieterman, BS, Sekhu Ansari, PhD2, Zachary Kincaid3, Mohammad Azhar4, Meenu Kesarwani, PhD, MSc5, Valentina Nardi, MD6, George Daley, MD, PhD7, Mohammad Azam Sr, PhD8
AFFILIATIONS
1 Cincinnati Childrens hospital Medical Center, Cincinnati, Ohio, United States
2 Cincinnati Childrens hospital Medical Center, Cincinnati, Ohio, United States
3 Cincinnati Childrens hospital Medical Center, Cincinnati, Ohio, United States
4 Cincinnati Childrens hospital Medical Center, Cincinnati, Ohio, United States
5 Cincinnati Childrens hospital Medical Center, Cincinnati, Ohio, United States
6 Boston childrens hospital, Boston, Massachusetts, United States
7 Boston childrens hospital, Boston, Massachusetts, United States
8 Cincinnati Childrens hospital Medical Center, Cincinnati, Ohio, United States
ABSTRACT
Despite major advances in targeting BCR::ABL1 in chronic myeloid leukemia (CML), acquired resistance and treatment failure remain significant clinical challenges. Even the most potent ABL kinase inhibitors select for compound mutations, which often include gatekeeper substitutions that confer cross-resistance to all currently approved ABL inhibitors. Combination therapy targeting both the ATP-binding pocket and an allosteric site of BCR::ABL1 has shown greater disease suppression and reduced emergence of resistance; however, given the adaptive capacity of the human genome, resistance to this combination strategy is expected to eventually emerge. Asciminib is being evaluated in combination with different ATP-site inhibitors, nilotinib, dasatinib, and ponatinib. The mutational spectrum underlying resistance to these combinations remains incompletely defined. We posit that each ATP-site inhibitor would impose distinct selection pressures when paired with the allosteric inhibitor asciminib, resulting in divergent resistance mechanisms. We performed resistance screening using randomly mutagenized BCR::ABL1, followed by selection of resistant clones exposed to asciminib in combination with one of four ATP-site inhibitors: dasatinib, nilotinib, ponatinib, or bosutinib. Resistant colonies were quantified and sequenced to identify the mutational landscape for each combination. Resistance frequencies differed markedly among asciminib-based combinations. Asciminib plus dasatinib generated the highest frequency of resistant clones, followed by asciminib plus nilotinib and asciminib plus ponatinib. In contrast, asciminib plus bosutinib yielded the lowest frequency (two resistant clones per 10 million cells screened), demonstrating the most effective suppression of resistance among all combinations tested. As envisioned, sequencing of these resistant clones revealed combination-specific mutational patterns. Resistance to asciminib + dasatinib was primarily driven by T315 gatekeeper mutations and SH2-domain mutations. Clones resistant to asciminib + nilotinib or asciminib + ponatinib frequently harbored T315I/M/F substitutions together with SH2 and/or SH3 domain deletions. Notably, resistance to these type II inhibitor combinations also involved recurrent mutations within the BCR region, a region not routinely sequenced in clinical resistance testing. The resistant colonies arising under asciminib + bosutinib carried only the T315I gatekeeper mutation. Reconstituted BCR-region and SH2/SH3 deletion mutants demonstrated increased kinase activity and resistance to asciminib in combination with nilotinib, ponatinib, and dasatinib but remained sensitive to asciminib + bosutinib, thereby confirming that the ascminib+bosutinib combination effectively suppressed resistance. This study identifies a previously unrecognized resistance mechanism involving mutations in the BCR region of BCR::ABL1 that are not currently assessed in standard clinical practice, highlighting the need to evaluate resistant patient samples lacking ABL1 kinase domain mutations for these variants. We are currently evaluating patient samples with TKI resistance in the absence of ABL1 kinase domain mutations to determine the prevalence and clinical significance of these BCR-region variants, and we will present the findings at the meeting. Importantly, among the combinations evaluated, asciminib + bosutinib most effectively suppressed the emergence of resistant clones. These data strongly encourage further clinical evaluation of the asciminib + bosutinib regimen for greater efficacy and to prevent the emergence of resistance. However, gatekeeper mutants will still pose a challenge to this combination, which our data suggest can be effectively suppressed with a triple combination of asciminib, axitinib, and bosutinib, providing a path forward for effective treatment outcomes even for highly resistant disease.
DISCLOSURES
Zachary Kincaid: No relevant conflicts of interest to declare.